Abbott Slightly Raises Profit Forecast on Strong Medical Device Sales
(Reuters) - Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong sales of its medical devices including its glucose-monitoring products.
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...
Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Bernstein analyst Lee Hambright maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target ...
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings ...
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback